Today's Hours: 8:00am - 6:00pm

Search

Did You Mean:

Search Results

  • Book
    Vinayak K. Prasad.
    Summary: "In this critical study of current cancer therapies, Dr. Prasad, an oncologist and hematologist, examines oncology practice and policy in the United States. His book is organized into four sections: (1) an overview of cancer drugs, (2) forces that distort cancer medicine and practice, (3) details about cancer research and practice, (4) recommended solutions on multiple levels (policy, practitioners, medical education, and pharmacology)"-- Provided by publisher.

    Contents:
    The Basics of Cancer Drugs : Cost, Benefit, Value
    Surrogate Endpoints in Cancer : What Are They and Where Are They Used?
    Use and Misuse of Surrogates for Drug Approvals
    How High Prices Harm Patients and Society
    Hype, Spin, and the Unbridled Enthusiasm That Distorts Cancer Medicine
    Financial Conflict of Interest
    The Harms of Financial Conflicts and How to Rehabilitate Medicine
    Will Precision Oncology Save Us?
    Study Design
    Principles of Oncology Practice
    Important Trials in Oncology
    Global Oncology
    How Should Cancer Drug Development Proceed?
    What Can the US Food and Drug Administration and the Centers for Medicare and
    Medicaid Services Do Tomorrow?
    What Can People with Cancer Do?
    What Can Students, Residents, and Fellows Do?
  • Article
    Berkman EM, Caplan S, Kim CS.
    Transfusion. 1978 Jul-Aug;18(4):504-8.
    The threat of fatal hemolytic transfusion reaction has been a major deterrent to the use of ABO-incompatible bone marrow donors. An eighteen year old type O male with acute leukemia was prepared to receive type A HLA identical marrow using large volume plasma exchange prior to and following cyclophosphamide administration. Saline agglutinating anti-A antibody was initially present at a titer of 1:128. The initial antiglobulin titer of dithiothreitol (DTT) treated serum was 1:64. Initially the T 1/2 of 51Cr labeled type A red blood cells was less than five minutes. The first plasma exchange removed large quantities of anti-A antibody but 51Cr survival of type A red blood cells was unchanged. A second plasma exchange after an interval of three days, increased the T 1/2 of 51Cr labeled cells to 20 minutes. Saline agglutinating anti-A was not present at a titer of 1:8 and the antiglobulin titer of DTT treated serum was 1:4. Reaction to subsequent transfusion of type A red blood cells (5 units) was limited to a single febrile episode during the first unit. Survival of 51Cr labeled red blood cells increased to T 1/2 equal to 21 hours. These data indicate that plasma exchange and infusion of ABO incompatible red blood cells effectively reduce antibody concentration and prolong survival of ABO incompatible erythrocytes. It is suggested that the prolongation of 51Cr survival of ABO-incompatible red blood cells to a point that extravascular destruction is predominant be used to establish the safety of ABO-incompatible marrow infusion.
    Digital Access Access Options